ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
AbbVie Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$282.68−2.74 (-0.96%)
Close on Oct 19, 2026
- Market cap
- $500.63B
- P/E (TTM)
- 79.9
- Dividend yield
- 2.35%
Share price
+$53.11 (+23.13%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsEx-dividend
AbbVie Inc. grew revenue 10.4% to $64.39B over the twelve months to Jun 30, 2026. Operating income rose 53.8% to $16.87B, moving the operating margin from 18.8% to 26.2%. Free cash flow was $18.21B, down 0.2% from a year earlier.
Revenue
$64.39B
+10.4% vs. a year earlier
Operating income
$16.87B
+53.8% vs. a year earlier
Free cash flow
$18.21B
-0.2% vs. a year earlier
EPS, diluted
$3.54
+68.6% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $500.63B
- P/E ratio
- 79.9
- Price to sales
- 7.78
- Price to book
- –
- Dividend yield
- 2.35%
- Free cash flow yield
- 3.64%
Fundamentals
- Revenue
- $64.39B
- Net income
- $6.31B
- EPS, diluted
- $3.54
- Free cash flow
- $18.21B
- Book value per share
- -$3.35
- Diluted shares
- 1.77B
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$64.39B+10.4% YoY
Gross profit
$46.02B+11.2% YoY
Operating income
$16.87B+53.8% YoY
Net income
$6.31B+67.7% YoY
EPS, diluted
$3.54+68.6% YoY
Free cash flow
$18.21B-0.2% YoY
Reported periodTrailing twelve months